LVRNA 021
Alternative Names: LVRNA-021; mRNA COVID-19 vaccineLatest Information Update: 22 Nov 2022
At a glance
- Originator AIM Vaccine
- Developer AIM Vaccine; First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 26 Sep 2022 Aim vaccine plans a clinical trial for Covid-2019 infections (Prevention) (IM) in September 2022 (NCT05547243)
- 26 Sep 2022 Aim vaccine initiates a cohort study for Covid-2019 infections (Prevention) in China (IM) in September 2022 (NCT05547243)
- 26 Sep 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in China (IM)(AIM Vaccine pipeline September 2022)